Avirmax, Inc.
PrivateLast Round
Series A
Nov 12, 2019
Total Funding Raised
$3M
Company Overview
Avirmax, Inc. is a biotechnology company that develops AAV-mediated gene therapies for ocular diseases and provides contract development and manufacturing (CDMO) services for viral vectors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Avirmax, Inc. Comparables
Compare Avirmax, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ascend Advanced Therapies | 85% | |
| PackGene Biotech | 84% | |
| VectorBuilder | 76% | |
Avirmax, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 12, 2019 |
Avirmax, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bencao Capital | Series A |
| Kaitai Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 12, 2019
$3M round with Bencao Capital and Kaitai Capital.
Avirmax, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Avirmax, Inc.'s valuation, stock price, and market status.